DAM
HZNP

Deimos Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Deimos Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,000
Closed -$166K – 138
2016
Q1 		$166K Buy
+10,000
New +$175K 0.12% 102

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Deimos Asset Management's HZNP Position: Q2 2016 in Review

Deimos Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 10,000 shares — an estimated $166K sold.

Deimos Asset Management first reported a position in HZNP in Q1 2016 and held it in 1 quarter. The position peaked at $166K in Q1 2016. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

  • Deimos Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
  • Deimos Asset Management sold 10,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $166K.
  • Deimos Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 1 quarter.
  • Deimos Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $166K in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Deimos Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.